ORIC Pharmaceuticals (NASDAQ: ORIC) provides enozertinib Phase 1b data update

Rhea-AI Filing Summary

ORIC Pharmaceuticals, Inc. provided a program update on its enozertinib (ORIC-114) candidate, presenting recently announced data from its Phase 1b trial. The update was delivered through a presentation included as Exhibit 99.1, giving stakeholders access to the detailed clinical information the company shared on this program.

false 0001796280 0001796280 2025-12-06 2025-12-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

December 6, 2025

ORIC Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-39269		47-1787157
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

240 E. Grand Ave, 2nd Floor

South San Francisco, CA 94080

(Address of principal executive offices, including zip code)

(650) 388-5600

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.0001 per share		ORIC		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Item 8.01 Other Events.

ORIC Pharmaceuticals, Inc. (the “Company”) presented an enozertinib (ORIC-114) program update (the “Program Update”) on December 6, 2025. The Program Update covered recently announced data from the Company’s Phase 1b trial of enozertinib. A presentation containing the data presented in the Program Update is attached as Exhibit 99.1 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number		Description
99.1		Presentation
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						ORIC PHARMACEUTICALS, INC.
Date: December 8, 2025				By:		/s/ Christian V. Kuhlen
						Christian V. Kuhlen, M.D., J.D.
						General Counsel

FAQ

What did ORIC Pharmaceuticals (ORIC) disclose in its latest SEC report?

ORIC Pharmaceuticals disclosed that it presented an enozertinib (ORIC-114) program update, covering recently announced data from its Phase 1b trial. The company made this information available through an attached presentation.

Which ORIC program is highlighted in this 8-K for ORIC Pharmaceuticals (ORIC)?

The report highlights ORIC's enozertinib (ORIC-114) program. The company presented an update focused on Phase 1b trial data for this investigational therapy.

What clinical stage data for ORIC Pharmaceuticals (ORIC) are discussed in the update?

The program update for ORIC Pharmaceuticals centers on Phase 1b trial data for enozertinib (ORIC-114), as noted in the company’s description of the presentation.

Where can investors find the detailed enozertinib (ORIC-114) data for ORIC Pharmaceuticals (ORIC)?

The detailed data are contained in a presentation attached as Exhibit 99.1 to the company’s current report. This exhibit includes the information presented in the enozertinib program update.

What exhibits did ORIC Pharmaceuticals (ORIC) file with this enozertinib update?

ORIC Pharmaceuticals filed Exhibit 99.1, a presentation containing the enozertinib (ORIC-114) Phase 1b data, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.